Evaluation of the teratogenic potential of pyrazinamide in Wistar rats.
We have tested Pyrazinamide (PZA), an essential component of modern short-course tuberculosis treatment regimen, for teratogenicity using Wistar rats. The drug was given by oral intubation from 6-15 days of gestation, at doses of 0, 25, 100 and 500 mg/kg body weight per day. Reduction in body weight and food consumption were observed in the treated dams. On day 20 of gestation, all the dams were killed by cervical dislocation and signs of maternal toxicity, reproductive indices and fetal measurements were recorded. Dams given doses of 100 and 500 mg/kg had significantly higher incidence of reabsorbed fetuses, reduced litter size, and impaired neonatal growth than those given no PZA or only 25 mg/kg dose. External visceral and skeletal examination of all fetuses of PZA-treated dams showed several types of variations which were neither dose related nor having a consistent pattern. However, these variations occurred mostly in the dams treated with the dose of 500 mg/kg. In conclusion, these data show that in Wistar rats, only high doses of PZA (100 and 500 mg/kg) produced fetotoxicity. No evidence of teratogenic effect of the drug was observed.
Al-Hajjaj
M S
MS
Department of Medicine, King Saud University, Riyadh, Saudi Arabia.
Al Haider
A K
AK
Islam
M W
MW
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology*; D001724:Birth Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005313:Fetal Death / Q000139:chemically induced; D005327:Fetal Resorption / Q000139:chemically induced; D005333:Fetus / Q000187:drug effects*; D015994:Incidence; D008297:Male; D011718:Pyrazinamide / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013723:Teratogens / Q000494:pharmacology*
D000995:Antitubercular Agents; D013723:Teratogens; D011718:Pyrazinamide